Researchers Develop Breakthrough COVID-19 Antibody Test with 1,000-Fold Sensitivity Improvement Using Quanterix’ Simoa Technology
Test deployed on
Non-exclusive agreement with Brigham and Women’s Hospital licensed technology to conduct serological assay to address unmet needs in the clinical setting, epidemiological studies, and for therapeutic and vaccine development
The multiplex serological assay, which was licensed by Brigham and Women’s Hospital to
“Reopening strategies will look different for every state and nation, but the undeniable fact is that they will require widespread antibody testing,” said
Using a combination of IgG, IgM and IgA responses to spike protein, the research team used the serological assay to test 81 plasma samples from
As the COVID-19 pandemic continues to infect millions of people worldwide, the ability to curb its spread and reduce mortality requires the development of sensitive methods that can identify infected individuals and enable accurate population-wide screening of both past and present infection. Currently, nucleic acid based tests of nasopharyngeal swabs are the primary method used to detect COVID-19 infected individuals; however, these tests can only diagnose disease during a narrow window of active infection with an overall lower clinical sensitivity of 65-72%. Additional diagnostic methods, therefore, are needed to identify those who are or have been infected with the virus.
“Uncovering new insights about immune response will be essential to our next steps as a global community,” continued Hrusovsky. “Our ultra-sensitive assay technology allows for earlier, more accurate detection using less invasive, small volume samples such as dried blood spots or capillary finger pricks that can be leveraged to maximize population testing reach into home sampling, as well as large sample dilutions to minimize matrix effects and false positives and negatives. We’re proud to be working closely with experts in the forefront of their fields, such as
Further details on Quanterix’ infectious disease offerings and educational resources, can be accessed here: https://www.quanterix.com/therapeutic-areas/infectious-disease.
For more information on
Details on the company’s homebrew services for developing customer Simoa assays are available here: https://www.quanterix.com/products-technology/homebrew.
COVID-19 investigators with questions about Simoa or who are in need of testing support are encouraged to contact our team at: https://www.quanterix.com/contact.
Learn more about how to get involved with
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the
Investor Relations Contact: